Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494645 · ClinicalTrials.gov registry record · Phase 4
Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery
A Phase 4 study, sponsored by St. Luke's Hospital, Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT05494645 is a Phase 4 study that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 248 participants.
The verdict
NCT05494645, a Phase 4 study, has completed, sponsored by St. Luke's Hospital, Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
Liposomal Bupivacaine (Exparel) has been recently studied as the active agent utilized in various nerve block. Due to its liposomal form allowing for extended delivery, Exparel has been used in various peri-operative nerve blocks among multiple orthopaedic specialties in hopes of achieving improved pain control and decreased opioid use. This study compares the efficacy and effect on opioid use of peripheral nerve blocks and local infiltration with and without Exparel in patients undergoing foot and ankle surgery.
Interventions
- DRUG Exparel
- DRUG Peripheral Nerve Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05494645
The ClinicalTrials.gov registry entry for NCT05494645 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's Hospital, Pennsylvania, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT05494645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05494645 about?
NCT05494645 is a clinical study titled "Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery". Liposomal Bupivacaine (Exparel) has been recently studied as the active agent utilized in various nerve block. Due to its liposomal form allowing for extended delivery, Exparel has been used in various peri-operative nerve blocks among multiple orthopaedic specialties in hopes of achieving improved ...
What is the current status of trial NCT05494645?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2022-03-01. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT05494645?
The interventions under investigation include: Exparel (DRUG), Peripheral Nerve Block (DRUG).
Who is sponsoring clinical trial NCT05494645?
This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.